| Market Capitalization (Millions $) |
77 |
| Shares
Outstanding (Millions) |
29 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-78 |
| Cash Flow (TTM) (Millions $) |
10 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aerovate Therapeutics Inc
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients suffering from serious cardiopulmonary diseases. The company is based in St. Paul, Minnesota, and was founded in 2018.
Aerovatees lead product candidate is AV-101, a nebulized inhaled sodium nitrite solution that is being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company also has a pipeline of clinical and preclinical stage product candidates, including AV-1501 (a small molecule therapy for idiopathic pulmonary fibrosis) and AV-1703 (a novel therapy for pulmonary hypertension that is still in preclinical development).
The companyes platform technology is based on the therapeutic potential of nitric oxide (NO), a molecule generated by endothelial cells that plays a critical role in pulmonary and cardiovascular health. Aerovatees proprietary platform allows for the stable and controlled delivery of NO to the lungs, with the goal of improving gas exchange, reducing inflammation, and potentially improving mortality and morbidity in patients with pulmonary and cardiovascular diseases.
Aerovate Therapeutics is led by a team of experienced biopharmaceutical industry veterans with a track record of developing and commercializing successful therapies for cardiovascular and pulmonary diseases. The company has raised almost $28 million in funding to date, including an $18 million Series A financing round in June 2019 led by Sofinnova Investments and other institutional investors.
In conclusion, Aerovate Therapeutics is an emerging biopharmaceutical company with a focused and innovative approach to developing transformative therapies for serious cardiopulmonary diseases. The companyes lead product candidate, AV-101, has the potential to address a significant unmet medical need in patients with PH-HFpEF, and the companyes pipeline of product candidates underscores the broad therapeutic potential of nitric oxide-based therapies in the treatment of pulmonary and cardiovascular diseases.
Company Address: 930 Winter Street Waltham 2451 MA
Company Phone Number: 443-2400 Stock Exchange / Ticker: NASDAQ AVTE
|
